

# Solving Cancer Together

**Strategic Priorities** 



Understand Cancer Biology Reduce the Cancer Burden Improve Cancer Care

**Research Platforms** 



Cell Therapy

**Preoperative Clinical Trials** 

**Data Science** 

**Enabling Strategies** 



**Network Engagement** 

**Trial Capabilities & Platforms** 

**Communication & Knowledge Transfer** 

**Sustainable Funding** 

2022-2027 STRATEGIC PLAN



#### **Understand cancer biology**

use this knowledge to improve cancer therapies & outcomes

This strategic priority will centre on trials of novel agents, cell therapy and pre-operative treatments while looking to increase sample collection, characterization, and cross-trial analyses. The Group will increase participation in precision medicine and rare cancer trials and expand the use of data and biospecimens by researchers.

#### Reduce the cancer burden

its treatment for patients & caregivers

Through this strategic priority, CCTG will develop a portfolio of trials and trial-related activities that will emphasize the assessment and reduction of the burden of treatment on patients and incorporate the patient perspective.

#### Improve cancer care

by demonstrating the value of cancer treatments

Through this strategic priority the CCTG will demonstrate the value of cancer treatments by assessing value of new technologies and existing treatments as well as engaging policy communities to define health technology assessment (HTA) criteria for cancer precision medicine diagnostics.



# **Cell Therapy**

CCTG is will continue advancing the evaluation of cellular and biological therapies for patients in clinical trials. A key component of CCTG's strategy to advance cell and biological therapies is its leadership and support of the ExCELLirate Canada platform.

## **Preoperative Clinical Trials**

The platform will have multidisciplinary expertise, support collection and analysis of specimens to understand treatment sensitivity and resistance, and it will also encourage and enable supportive management to improve clinical outcomes and quality of life of patients.

#### **Data Science**

The Data Science Platform will expand capacity in the following three areas: data science (data infrastructure and analysis), digital technologies, and real-world evidence. The platform will improve data collection, aggregation and analysis to inform trial outcomes and provide data to the broader research community.



## **Network Engagement**

CCTG network engagement activities will focus on continuing and strengthening network leadership, governance, research collaborations, and patient engagement. It will also provide career development and educational opportunities for CCTG members.

### **Trial Capabilities & Platforms**

CCTG trial capabilities and platforms ensure timely, effective development and conduct of phase I-III trials that optimize data management, specimen collection, tracking, and processing and its systems, technologies and processes meet the needs of the network.

### **Communication & Knowledge Transfer**

CCTG will develop an integrated approach to communications marketing, education, and knowledge translation that will meet the needs of CCTG's leaders and network members while promoting the knowledge of CCTG activities and its impact to the broader community.

### **Sustainable Funding**

CCTG aims to sustain its activities by successfully renewing and maintaining current funding, and identifying and competing successfully for new funding.

